Cantargia Management

Management criteria checks 3/4

Cantargia's CEO is Goran Forsberg, appointed in Jun 2014, has a tenure of 9.83 years. total yearly compensation is SEK5.40M, comprised of 44% salary and 56% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth €89.11K. The average tenure of the management team and the board of directors is 2.3 years and 3.5 years respectively.

Key information

Goran Forsberg

Chief executive officer

kr5.4m

Total compensation

CEO salary percentage	44.0%
CEO tenure	9.8yrs
CEO ownership	0.2%
Management average tenure	2.3yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Goran Forsberg's remuneration changed compared to Cantargia's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr5m	kr2m	-kr280m
Sep 30 2023	n/a	n/a	-kr299m
Jun 30 2023	n/a	n/a	-kr293m
Mar 31 2023	n/a	n/a	-kr330m
Dec 31 2022	kr5m	kr2m	-kr372m
Sep 30 2022	n/a	n/a	-kr385m
Jun 30 2022	n/a	n/a	-kr419m
Mar 31 2022	n/a	n/a	-kr411m
Dec 31 2021	kr5m	kr2m	-kr367m
Sep 30 2021	n/a	n/a	-kr319m
Jun 30 2021	n/a	n/a	-kr255m
Mar 31 2021	n/a	n/a	-kr206m
Dec 31 2020	kr6m	kr2m	-kr173m
Sep 30 2020	n/a	n/a	-kr153m
Jun 30 2020	n/a	n/a	-kr139m
Mar 31 2020	n/a	n/a	-kr127m
Dec 31 2019	kr4m	kr2m	-kr111m
Sep 30 2019	n/a	n/a	-kr102m
Jun 30 2019	n/a	n/a	-kr98m
Mar 31 2019	n/a	n/a	-kr101m
Dec 31 2018	kr3m	kr1m	-kr91m
Sep 30 2018	n/a	n/a	-kr78m
Jun 30 2018	n/a	n/a	-kr68m
Mar 31 2018	n/a	n/a	-kr56m
Dec 31 2017	kr3m	kr1m	-kr60m

Compensation vs Market: Goran's total compensation ($USD494.50K) is about average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Goran's compensation has increased whilst the company is unprofitable.

CEO

Goran Forsberg (60 yo)

9.8yrs

Tenure

kr5,404,000

Compensation

Mr. Goran Forsberg has been Independent Director at Guard Therapeutics International AB (publ) since May 2019. He has been the Chief Executive Officer at Cantargia AB (publ) since June 2014. Mr. Forsberg s...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Goran Forsberg	Chief Executive Officer	9.8yrs	kr5.40m	0.17% SEK 89.1k
Thoas Fioretos	Founder & Scientific Advisor	no data	kr355.00k	no data
Marcus Järås	Founder & Scientific Advisor	no data	no data	no data
Kjell Sjöström	Founder	no data	no data	no data
Patrik Renblad	Chief Financial Officer	less than a year	no data	no data
Liselotte Larsson	Chief Operating Officer	10.3yrs	no data	0.035% SEK 18.9k
David Liberg	Chief Scientific Officer	less than a year	no data	no data
Nina Valkama	Executive Assistant of Administration & Finance	2.3yrs	no data	no data
Dominique Tersago	Chief Medical Officer	1.7yrs	no data	no data
Johanna Christensen	Financial Controller	2.3yrs	no data	no data

2.3yrs

Average Tenure

60yo

Average Age

Experienced Management: 7V3's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gunnar Magnus Severus Persson	Independent Chairman of the Board	8.3yrs	kr854.00k	no data
Damian Marron	Independent Director	2.9yrs	kr350.00k	no data
Anders Martin-Lof	Independent Director	5.9yrs	kr473.00k	no data
Magnus Nilsson	Independent Director	2.9yrs	kr342.00k	no data
Flavia Borellini	Independent Director	3.5yrs	kr550.00k	no data

3.5yrs

Average Tenure

63yo

Average Age

Experienced Board: 7V3's board of directors are considered experienced (3.5 years average tenure).

Cantargia Management

Management criteria checks 3/4

Key information

Recent management updates

Cantargia AB (publ), Annual General Meeting, May 23, 2024

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Cantargia AB (Publ) Announces Nomination Committee Appointments

Cantargia AB (Publ) Announces Executive Changes

Chief Financial Officer recently bought €23k worth of stock

Recent updates

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells

Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy

Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis

Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10

Cantargia AB (Publ) Announces Executive Changes

Cantargia Announces ASCO 2022 Presentation Strengthens Positive Phase IIa interim results for nadunolimab in NSCLC

Cantargia AB (publ) Presents Clinical Interim Results At ASCO 2022 Highlighting the Potential of Nadunolimab in Combination with Checkpoint Inhibitor

Cantargia AB (publ) Reports Positive Preclinical Effects in Atherosclerosis Demonstrating Potential of Can10 in Cardiovascular Disease

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Cantargia Reports Positive Preclinical Efficacy Data for CAN10 Demonstrating Anti-Fibrotic and Anti-Inflammatory Effects in Systemic Sclerosis

Cantargia AB (Publ) Reports Encouraging New CAN10 Toxicology Results and Schedules Phase I Trial for 2023

Cantargia AB Reports Treatment of First Non-Squamous Non-Small Cell Lung Cancer Patient in New Arm of CANFOUR Study

Cantargia Reports Positive Safety Data from Cirifour Clinical Study on Nadunolimab and Pembrolizumab Combination

Cantargia AB (Publ) Reports Treatment of First Triple Negative Breast Cancer Patient in TRIFOUR Study

Cantargia Advances Nadunolimab Against Pancreatic Cancer in the Pancan Precision Promise[Sm] Phase 2/3 Clinical Trial

Cantargia AB (publ) Reports Updated Encouraging Survival Data from CANFOUR Trial with Nadunolimab and Chemotherapy in Pancreatic Cancer

Cantargia AB (publ) Reports Positive Results for Can10 Antibody in Preclinical Systemic Sclerosis Model

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Cantargia AB (Publ) Announces New Positive Interim Results on Nadunolimab Combination Therapy in NSCLC Published in Abstract for the Annual ESMO Congress

Cantargia AB Completes Patient Recruitment to the Phase IIa Pancreatic Cancer Extension Cohort in the CANFOUR Study

Cantargia AB Reports Preclinical Data Highlighting Advantages of Nadunolimab Mechanism of Action

Cantargia AB Reports First Patient Treated in CAPAFOUR Study Investigating Combination of Nadunolimab with FOLFIRINOX in Pancreatic Cancer

Cantargia Expands CIRIFOUR Trial After Successful Completion of Recruitment in the Pembrolizumab Combination Arm

Cantargia Advances Development of Nadunolimab in Triple Negative Breast Cancer Through Submission of Clinical Protocol for TRIFOUR Study

Cantargia AB (publ) Broadens the Development of Nadunolimab in Three Forms of Cancer and Submits Application for the Phase I/II Clinical Trial CESTAFOUR

Cantargia Receives Regulatory Approval to Start Clinical Trial Investigating Nadunolimab and FOLFIRINOX in Pancreatic Cancer

Chief Financial Officer recently bought €23k worth of stock

Cantargia AB (Publ) Reports Positive Results in Ongoing Phase IIa Clinical Trial in Pancreatic Cancer Using Nadunolimab and Chemotherapy

Cantargia AB Presents New Preclinical Data Showing Unique Improvement of Heart Function in Myocarditis Using Antibody CAN10

Cantargia AB (Publ) Advance Development of Antibody Can04 by A New Clinical Trial in Triple Negative Breast Cancer

Cantargia AB Presents New Preclinical Data on Antibody CAN10 At Immmunology2021